playnext.fm

The Optimal Body

453 | GLP-1 Benefits: The Facts and Myths for Obesity, Weight Loss, and Beyond with Dr Spencer Nadolsky

·1 hr 3 min·5 clips
Dr. Spencer Nadolsky reveals why blaming yourself for weight loss failure actually makes it harder to succeed.
The episode begins with an ad for Manuka honey before introducing Dr. Spencer Nadolsky, a board-certified obesity medicine and lipidology specialist. Dr. Nadolsky shares his career path, explaining he was drawn to obesity medicine because helping people go from nothing to something was more fulfilling than sports performance. He discusses the stigma around weight loss, emphasizing that self-blame worsens outcomes and reframing obesity as biological, where appetite increases fight against weight loss. The history of GLP-1 drugs is covered, from the incretin effect discovered in the 1960s to the role of Gila monster venom in developing the first GLP-1 drug, exenatide, in 2007. Dr. Nadolsky explains how semaglutide (Ozempic/Wegovy) achieves about 15% total body weight loss, compared to 6-7% with lifestyle changes and 25-30% with bariatric surgery. He predicts bariatric surgery will become rarer as GLP-1 drugs improve. Beyond weight loss, GLP-1s show benefits for cardiovascular disease, sleep apnea, osteoarthritis, and autoimmune conditions like Crohn's disease and psoriasis, with some effects independent of weight loss. Dr. Nadolsky addresses risks, including GI side effects, gallbladder issues, and weight cycling for non-indicated use. He notes most people need to continue GLP-1s long-term to maintain weight loss, similar to chronic disease management. The discussion covers safety concerns, such as compounded versions potentially containing impurities, and contraindications like medullary thyroid cancer. Future developments include oral versions like oral Wegovy and orforglipron, and combination drugs like tirzepatide (Mounjaro/Zepbound) and retatrutide. The episode ends with Dr. Nadolsky's thoughts on health differences between the US and Europe, attributing them to social determinants and cultural factors.

As heard by us

A careful look at what GLP-1 drugs may influence beyond weight loss, and where the uncertainty still matters.

GLP-1 drugs sit at the center of this PlayNext review as Dr. Jen and Dr. Dom press their guest on what these medications might do beyond weight loss. The conversation starts with glucose handling and insulin, then widens into the metabolic strain linked with chronic conditions.

Read the full review in PlayNext →

Why you'd press play

You want the GLP-1 conversation to move past weight loss headlines and into the messier biology underneath.

Read the full recommendation in PlayNext →
Listen to the show on
Apple PodcastsSpotify
Play clips from this episodeMore from The Optimal Body